Alkermes (ALKS) Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ALKS Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alkermes plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$45.40 |
| 52 Week High | US$55.67 |
| 52 Week Low | US$26.40 |
| Beta | 0.26 |
| 1 Month Change | -8.10% |
| 3 Month Change | 1.07% |
| 1 Year Change | 68.59% |
| 3 Year Change | 52.30% |
| 5 Year Change | 47.93% |
| Change since IPO | 725.45% |
Recent News & Updates
Narrative Update • Aug 19
ALKS: Orexin Pipeline Data Will Drive Future Upside Potential
The Alkermes analyst price target in this narrative update shifts from $47.69 to $56.00, reflecting analysts' use of recent upward Street target revisions and stronger profit margin assumptions tied to continued commercial and orexin pipeline execution. Analyst Commentary Recent research on Alkermes highlights a mix of optimism around the orexin pipeline and sleep portfolio, alongside pointed concerns about execution risk and current valuation.
Narrative Update • Aug 05
ALKS: Orexin Sleep Pipeline And IH Data Will Drive Future Upside
Alkermes' analyst fair value estimate has been updated from $65.00 to $72.00 as analysts factor in a higher profit margin outlook, continued commercial and orexin pipeline execution, and a series of recent price target increases across the Street. Analyst Commentary Recent research coverage on Alkermes shows a wide range of views, with many bullish analysts lifting price targets as they update models for orexin assets, sleep disorder indications, and attention deficit hyperactivity disorder opportunities.Recent updates
Narrative Update • Aug 19
ALKS: Orexin Pipeline Data Will Drive Future Upside Potential
The Alkermes analyst price target in this narrative update shifts from $47.69 to $56.00, reflecting analysts' use of recent upward Street target revisions and stronger profit margin assumptions tied to continued commercial and orexin pipeline execution. Analyst Commentary Recent research on Alkermes highlights a mix of optimism around the orexin pipeline and sleep portfolio, alongside pointed concerns about execution risk and current valuation.Narrative Update • Aug 05
ALKS: Orexin Sleep Pipeline And IH Data Will Drive Future Upside
Alkermes' analyst fair value estimate has been updated from $65.00 to $72.00 as analysts factor in a higher profit margin outlook, continued commercial and orexin pipeline execution, and a series of recent price target increases across the Street. Analyst Commentary Recent research coverage on Alkermes shows a wide range of views, with many bullish analysts lifting price targets as they update models for orexin assets, sleep disorder indications, and attention deficit hyperactivity disorder opportunities.
Narrative Update • Jul 22
ALKS: Orexin Pipeline Execution Will Drive Future Downside Risk For Sleep Franchise
Analysts have raised Alkermes' fair value estimate from $31.30 to $38.00, reflecting updated assumptions around the orexin pipeline, recent price target increases across the Street, and mixed views on current valuation after the stock's recent performance. Analyst Commentary Recent research on Alkermes highlights a mix of enthusiasm for the orexin franchise and growing debate about how much good news is already reflected in the stock.Narrative Update • Jul 08
ALKS: Orexin And IH Pipeline Progress Will Drive Future Upside
Analysts have lifted the Alkermes fair value estimate to $65.00 from $58.37, citing higher assumed market share for alixorexton in narcolepsy type 2 and incremental value for ALKS-7290 in the ADHD market, even as some caution that recent share gains already price in very strong execution on the orexin pipeline. Analyst Commentary Recent Street research around Alkermes highlights a split view, with several bullish analysts lifting price targets on the back of the orexin portfolio and ADHD optionality, while at least one major bank flags execution risk after a strong share price run.Narrative Update • Jun 24
ALKS: Sleep Disorder Data And Orexin Franchise Will Set Balanced Upside Potential
Alkermes' updated analyst price target edges higher to $47.69 from $44.24, with analysts pointing to reinforced confidence in the orexin franchise, including alixorexton's broader narcolepsy data and the implied potential in idiopathic hypersomnia and ADHD. This comes even as modeled revenue growth moderates and profit margin assumptions increase.Seeking Alpha • Jun 19
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
Summary Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis. ALKS projects full-year 2026 revenues of between $1.73 and $1.84 billion, supported by four approved drugs, though phase 3 trial risks and integration remain. Read the full article on Seeking AlphaNarrative Update • Jun 09
ALKS: Sleep Disorder Pipeline And IH sNDA Timeline Will Drive Future Upside
The analyst price target for Alkermes has been raised by $1.80, with analysts citing positive IH Phase 3 data and updated models regarding potential sNDA timing as key drivers of the change. Analyst Commentary Bullish analysts are treating the recent IH Phase 3 data as a key input to their updated models, with some price targets for Alkermes being lifted to reflect potential sNDA timing and a clearer roadmap for the program.Narrative Update • May 26
ALKS: Sleep Disorder Pipeline Progress Will Drive Future Upside Potential
Analysts have nudged Alkermes' fair value estimate slightly lower to $56.57 from $57.33, even as they raise price targets into the mid to high $40s, supported by positive Phase 3 sleep data and a growing focus on the Lumryz-anchored franchise and late-stage alixorexant program. Analyst Commentary Bullish analysts are clustering around a similar narrative for Alkermes, pointing to positive Phase 3 data in idiopathic hypersomnia, Lumryz as the current commercial anchor, and the progression of alixorexant as key pieces of the story.Analysis Article • May 12
Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings
Soft earnings didn't appear to concern Alkermes plc's ( NASDAQ:ALKS ) shareholders over the last week. We did some...Narrative Update • May 01
ALKS: Sleep And Narcolepsy Franchise Will Drive Future Upside Potential
Analysts have nudged Alkermes' fair value estimate slightly higher to about $57.33, reflecting updated assumptions for revenue growth, stronger margins and a lower future P/E that are echoed in recent price target revisions and commentary around the company's sleep and narcolepsy franchises. Analyst Commentary Recent research on Alkermes points to a mixed but generally constructive backdrop, with several bullish analysts emphasizing the potential of the sleep and narcolepsy portfolio and its impact on valuation assumptions.Narrative Update • Apr 16
ALKS: Sleep Franchise And Orexin Program Will Shape Future Upside Potential
Narrative Update: Alkermes Analyst Price Target Shift The updated analyst price target for Alkermes moves modestly higher by about $0.53, as analysts factor in revised assumptions around revenue growth, profit margins, and a higher future P/E, tied in part to the evolving sleep and narcolepsy franchise following recent research updates. Analyst Commentary Recent research on Alkermes reflects a mix of optimism around the sleep and narcolepsy portfolio and caution on execution, pricing assumptions, and the performance of legacy products.Narrative Update • Apr 01
ALKS: Sleep Franchise And Orexin Pipeline Will Drive Future Upside
Analysts made a small upward adjustment in the price target for Alkermes to about $43.71, supported by refreshed models around the company's emerging sleep and narcolepsy franchise, recent M&A activity in the biotech space, and updated views on future P/E multiples and profitability. Analyst Commentary Recent Street research on Alkermes circles around how the emerging sleep and narcolepsy franchise, the Avadel acquisition, and updated pricing assumptions could feed into growth expectations, while also flagging execution and valuation risks.Narrative Update • Mar 18
ALKS: Sleep Franchise And Orexin Breakthrough Will Drive Future Upside Potential
Narrative Update The updated analyst price target for Alkermes moves to $31.30 from $30.00, as analysts factor in revised revenue growth assumptions tied to the expanding sleep and narcolepsy franchise and the completed Avadel acquisition, along with adjusted views on profit margins and future P/E. Analyst Commentary Recent Street research on Alkermes presents a mixed picture, with analysts weighing the potential of the sleep and narcolepsy franchise against execution and valuation questions.Narrative Update • Mar 04
ALKS: Emerging Sleep Franchise And Orexin Program Will Drive Future Upside
Narrative Update on Alkermes The updated analyst price target for Alkermes edges down from $43.75 to about $43.65, as analysts balance slightly higher modeled revenue growth with lower profit margin assumptions and a higher future P/E tied to the growing sleep and narcolepsy franchise, including Lumryz and the orexin program. Analyst Commentary Recent Street research on Alkermes presents a mixed picture, with some analysts leaning constructive on the emerging sleep and narcolepsy portfolio and others more restrained on valuation and execution risk.Narrative Update • Feb 18
ALKS: Improved CVR Offer Terms Will Support Future Sleep Disorder Leadership
Analysts have slightly lowered their price target on Alkermes to $43.75 from $43.81, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E after reviewing the company's revised offer terms highlighted in recent Street research. Analyst Commentary Recent Street research around Alkermes is centered on the revised offer terms, especially the contingent value right, or CVR, structure that sits alongside the upfront consideration.Narrative Update • Feb 04
ALKS: Avadel Bid And Orexin Breakthrough Status Will Support Future Sleep Leadership
Analysts kept their Alkermes fair value estimate steady at about $43.81 per share while nudging up projected revenue growth and future P/E assumptions and trimming profit margin expectations, reflecting mixed reactions to the latest narcolepsy data and the evolving Avadel bid. Analyst Commentary Street research around Alkermes focuses on the mixed narcolepsy data, the competitive orexin pipeline, and the evolving Avadel bid, with investors weighing both upside optionality and execution risks.Narrative Update • Jan 20
ALKS: Avadel Sleep Deal And Orexin Breakthrough Designation Will Drive Upside
Analysts have trimmed their Alkermes price target by a small amount to reflect a slightly higher discount rate and somewhat lower expected profit margin, while still factoring in stronger modeled revenue growth and updated views on the Avadel acquisition and alixorexton sleep pipeline data. Analyst Commentary Bullish analysts are generally framing the recent updates around Alkermes as a mixed but constructive setup, with the Avadel acquisition and alixorexton data keeping the stock firmly on institutional radar.Narrative Update • Jan 06
ALKS: Sleep Franchise Acquisition Will Drive Future Orexin Class Leadership
Analysts have trimmed their Alkermes fair value estimate by about $0.06 per share to $43.81 as they weigh mixed alixorexton data against generally positive views on the Avadel acquisition and Alkermes' role in the emerging orexin class. Analyst Commentary Street research around Alkermes and its sleep portfolio is split between enthusiasm for the Avadel acquisition and orexin opportunity, and caution around alixorexton data quality and competitive pressures.Narrative Update • Dec 20
ALKS: Avadel Deal And Sleep Franchise Are Poised To Drive Upside
The analyst price target for Alkermes has been raised by about $4 to approximately $57 per share, as analysts factor in stronger expected revenue growth and profit margins supported by the strategic Avadel acquisition and resilient alixorexton sleep-disorder franchise prospects. Analyst Commentary Bullish analysts emphasize that the Avadel transaction, combined with a clearer outlook for alixorexton in narcolepsy and hypersomnia, materially improves Alkermes' growth, margin, and capital allocation story.Narrative Update • Dec 06
ALKS: Sleep Medicine Acquisition Will Drive Future Orexin Opportunity Upside
Analysts modestly lift their price target on Alkermes, reflecting confidence that the strategically priced Avadel acquisition, solid narcolepsy data and an underappreciated orexin class opportunity can drive upside, despite only incremental changes to long term growth and profitability assumptions. Analyst Commentary Street views on Alkermes remain mixed, with a generally constructive stance on long term positioning in sleep medicine and orexin agonists, tempered by questions around differentiation, safety profile and competitive intensity.Narrative Update • Nov 21
ALKS: Sleep Medicine Acquisition Will Drive Momentum After Narcolepsy Study Results
Analysts have slightly reduced their price target for Alkermes to $43.88 from $44, reflecting tempered revenue growth assumptions and competitive data from recent narcolepsy studies. Analyst Commentary Analyst sentiment regarding Alkermes remains divided following the latest developments in its narcolepsy franchise and pending acquisition of Avadel Pharmaceuticals.Narrative Update • Nov 06
ALKS: Clinical Progress In Narcolepsy Will Drive Share Momentum This Fall
Analysts have raised their fair value estimate for Alkermes from $42.53 to $44.00 per share. They cite stronger revenue growth forecasts and recent clinical and strategic updates, which improve the company's near- and mid-term outlook.Analysis Article • Oct 31
Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next
As you might know, Alkermes plc ( NASDAQ:ALKS ) just kicked off its latest third-quarter results with some very strong...Narrative Update • Oct 22
Analyst Commentary Highlights Growth Prospects and Risks Following Alkermes Acquisition and Updated Valuation
Alkermes' analyst price target was raised approximately $0.95 to $42.53 per share, as analysts point to improved profit margin outlook and the anticipated benefits from its Avadel Pharmaceuticals acquisition. These factors are expected to support both near- and mid-term growth.Seeking Alpha • Feb 25
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Summary Recently, Alkermes refocused on neuroscience, and now it’s dealing with stabilizing revenues from core products like Lybalvi, Vivitrol, Aristada, and Vumerity. However, the main growth driver going forward will be ALKS 2680. This is a once-daily oral OX2R agonist for narcolepsy treatment. ALKS is also now debt‑free with strong cash reserves and positive cash flow. So, it should be able to self fund its new bet on ALKS 2680. Their key Phase 2 trials are currently with Vibrance‑1 and Vibrance‑2, which could give us a clearer picture of ALKS 2680’s true potential. I accept ALKS trades at a slight premium relative to its peers, but it has robust financials and great cash flow to bet on ALKS 2680. So, I reiterate my “Buy” on ALKS stock. Read the full article on Seeking AlphaSeeking Alpha • Nov 24
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Summary Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a positive cash flow of $73.3 million in Q3, Alkermes can effectively fund R&D and operations. Risks include potential clinical trial failures for ALKS 2680 and competitive pressures in the CNS market, but long-term prospects remain favorable. Despite trading near fair value, ALKS's robust financials and positive cash flow support its R&D and potential future growth, making it a viable "buy on dips" stock. Read the full article on Seeking Alpha
New Narrative • Aug 31
Robust Product Demand And Critical Innovations Set To Propel Growth, Amid Analysts' Concerns And Revenue Diversification Challenges
Proprietary products and strategic sales like the Athlone facility sale signal robust revenue growth and operational efficiency, showing promise for future earnings.Seeking Alpha • Jul 28
Alkermes: Fairly Valued After Post-Earnings Bump
Summary Today, we take a look at Alkermes plc, a mid-cap biopharma company headquartered in Dublin, Ireland. The company has several products on the market and the stock has moved up 15% in the past two weeks, thanks to sector rotation and solid Q2 results. Management has done a solid job in recent quarters streamlining the company, and Alkermes also has a significant stock buyback program. The shares still trade under 11 times forward earnings. Still more upside ahead? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaShareholder Returns
| ALKS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.9% | -2.6% | 0.9% |
| 1Y | 68.6% | 38.4% | 15.5% |
Return vs Industry: ALKS exceeded the US Biotechs industry which returned 38.4% over the past year.
Return vs Market: ALKS exceeded the US Market which returned 15.5% over the past year.
Price Volatility
| ALKS volatility | |
|---|---|
| ALKS Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALKS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALKS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 2,050 | Blair Jackson | www.alkermes.com |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
Alkermes plc Fundamentals Summary
| ALKS fundamental statistics | |
|---|---|
| Market cap | US$7.63b |
| Earnings (TTM) | US$66.12m |
| Revenue (TTM) | US$1.67b |
115.2x
P/E Ratio4.6x
P/S RatioIs ALKS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALKS income statement (TTM) | |
|---|---|
| Revenue | US$1.67b |
| Cost of Revenue | US$213.76m |
| Gross Profit | US$1.45b |
| Other Expenses | US$1.39b |
| Earnings | US$66.12m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.39 |
| Gross Margin | 87.18% |
| Net Profit Margin | 3.97% |
| Debt/Equity Ratio | 83.1% |
How did ALKS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 21:44 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alkermes plc is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Luke Herrmann | Baird |